FDA approves first topical gel to ease redness of rosacea

FDA approves 1st topical gel to ease redness of rosacea
Mirvaso works by constricting dilated blood vessels of the face, company says.

(HealthDay)—Patients with the common skin condition rosacea can now turn to the first topical gel aimed at easing the redness that comes with the ailment.

The U.S. Food and Drug Administration on Monday approved Mirvaso (brimonidine) for the treatment of the redness—clinically known as erythema—that is a hallmark of rosacea. The gel is made by Galderma Laboratories, of Fort Worth, Texas, and was approved based on two month-long clinical trials involving more than 550 patients.

"Facial redness is the most common symptom of rosacea, but until now, physicians have been without prescription treatment options to specifically address this patient need," lead investigator Dr. Mark Jackson, a dermatologist and clinical professor of medicine at the University of Louisville in Kentucky, said in a news release from Galderma.

"The FDA approval of Mirvaso marks a turning point in rosacea treatment: we are now able to provide patients that deal with the daily frustrations caused by the redness of rosacea with an ," he said.

One skin expert not connected to the company agreed.

"Up until this point, we have only had drugs to treat the bumps and pus pimples of rosacea," said Dr. Joshua Zeichner, director of cosmetic and clinical research in the department of dermatology at Mount Sinai Medical Center, in New York City. "The approval of Mirvaso is very exciting because for the first time, we have a medication to treat facial redness of rosacea, which previously could only be addressed with lasers. Facial redness is a significant issue for rosacea patients, so this drug will fill a large, unmet need."

Rosacea is a chronic inflammatory and vascular ailment that affects the face, causing redness and visible blood vessels as blemishes appear on the forehead, nose and cheeks. The condition is most common in people over 30 and is thought to affect about 16 million Americans, according to the news release.

The studies that led to Mirvaso's approval showed that the drug outperformed an inactive placebo gel in providing "significantly greater improvement in the facial redness of rosacea," the Galderma release said. Another trial, involving 276 patients, was conducted for a year.

According to the company, Mirvaso is thought to work by constricting otherwise dilated facial blood vessels, cutting down on the appearance of redness. The gel is applied once a day to the forehead, chin, nose and cheeks, Galderma said. It will be available in pharmacies in September.

Another dermatologist cautioned that Mirvaso should not be seen as a cure for rosacea.

"This will not replace the need for other rosacea treatments for control of breakouts," said Dr. Doris Day, a dermatologist at Lenox Hill Hospital in New York City. However, she said, existing rosacea therapies "have been limited in their ability to treat or control redness."

Side effects from Mirvaso were rare. In the year-long study, less than 4 percent of the patients experienced reactions such as flushing, redness, burning sensations or headache, the company said. The gel is currently indicated for adults aged 18 or older, and should only be used "with caution" by people affected by depression or certain heart or autoimmune disorders.

More information: To find out more about rosacea, head to the National Rosacea Society.

add to favorites email to friend print save as pdf

Related Stories

Epidemiology of rosacea described in United Kingdom

May 21, 2012

(HealthDay) -- The incidence of rosacea in the United Kingdom is 1.65 per 1,000 person-years, with alcohol consumption linked to a modest increase in risk and current smoking linked to an decreased risk, according to a study ...

Bacterial cause found for skin condition rosacea

Aug 29, 2012

Scientists are closer to establishing a definitive bacterial cause for the skin condition rosacea. This will allow more targeted, effective treatments to be developed for sufferers, according to a review published in the ...

Simponi approved for ulcerative colitis

May 15, 2013

(HealthDay)—Simponi (golimumab) injection has been approved by the U.S. Food and Drug Administration to treat adults with moderate-to-severe ulcerative colitis.

Aesthetician reports on the beauty benefits of oils

Sep 26, 2011

Oils can have several protective benefits for all skin and body types. However, deciphering which oils to use for which skin type can be confusing. Aimee Masi of the Loyola Center for Aesthetics works with her patients to ...

Recommended for you

Determine patient preferences by means of conjoint analysis

17 hours ago

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

User comments